[{"id":"6560b97b-3122-44cd-a865-71153299925a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=03bae657cb794093a19e6e76a059f51f","created_at":"2026-06-27T01:56:19.186Z","updated_at":"2026-06-27T01:56:19.186Z","phase":"Phase 3","brief_title":"A phase III randomized study evaluating the use of Dato-DXd and durvalumab injections before and after surgery in adult breast cancer patients.","source_id_and_acronym":"CTR20240839","lead_sponsor":"Daiichi Sankyo, Inc. / AstraZeneca Investment (China) Co., Ltd. / Baxter Oncology GmbH","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 04/18/2024","start_date":" 04/18/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"88cbaec6-726c-463c-b500-e2906c28c31a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=32610da6ed78414b84d12529fcfe75ef","created_at":"2026-06-27T02:27:50.193Z","updated_at":"2026-06-27T02:27:50.193Z","phase":"Phase 3","brief_title":"A study comparing the efficacy and safety of GLOOFITAMAB plus vepotuzumab + rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) versus POLA-R-CHP in patients with untreated large B-cell lymphoma.","source_id_and_acronym":"CTR20232656","lead_sponsor":"F. Hoffmann-La Roche Ltd / Genentech, Inc. (Roche (China) Investment Co., Ltd.)","biomarkers":" ALK • BCL2 • CD20 • CD4","pipe":" | ","alterations":" ALK positive • CD20 positive","tags":["ALK • BCL2 • CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Columvi (glofitamab-gxbm)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"955259b7-960d-4044-8111-fc9e80956b11","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=e4ff786d66cc46f596ab6059f772e637","created_at":"2026-06-27T02:10:16.484Z","updated_at":"2026-06-27T02:10:16.484Z","phase":"Phase 3","brief_title":"A phase III clinical trial evaluating fruquintinib in combination with sintilimab for the treatment of advanced endometrial cancer.","source_id_and_acronym":"CTR20242784","lead_sponsor":"Hutchison MediPharma (Suzhou) Co., Ltd. / Hutchison MediPharma (Shanghai) Co., Ltd.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • doxorubicin hydrochloride • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 412","initiation":"Initiation: 12/12/2024","start_date":" 12/12/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"bbb660e6-4fd5-4c25-bd33-3079a966cda9","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=9ed65dd6d8d649269686adcf384f54de","created_at":"2026-06-27T02:06:07.671Z","updated_at":"2026-06-27T02:06:07.671Z","phase":"Phase 3","brief_title":"A study comparing the efficacy and safety of Golcadomide plus R-CHOP versus placebo plus R-CHOP in treatment-naïve high-risk large B-cell lymphoma patients.","source_id_and_acronym":"CTR20242203","lead_sponsor":"Celgene Corporation / Bristol Myers Squibb (China) Investment Co., Ltd.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • golcadomide (CC-99282)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 09/09/2024","start_date":" 09/09/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"e8963d68-fda5-4b49-bec3-377a70d6a5f1","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bff6302bad2b420083fe71d853bfc18a","created_at":"2026-06-27T02:20:06.842Z","updated_at":"2026-06-27T02:20:06.842Z","phase":"Phase 3","brief_title":"A study evaluating changes in disease activity in newly diagnosed adult subjects with diffuse large B-cell lymphoma (DLBCL) using subcutaneous (SC) epcoritamab in combination with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP alone.","source_id_and_acronym":"CTR20231626","lead_sponsor":"AbbVie Inc. / AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. / Vetter Pharma-Fertigung GmbH \u0026 Co.KG","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"f6b1268a-1a2e-41ab-ad96-ab7bb3da3000","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=b4d288edb01a4d1bb73c3ffa55d8bcdc","created_at":"2026-06-27T02:20:07.414Z","updated_at":"2026-06-27T02:20:07.414Z","phase":"Phase 3","brief_title":"A study evaluating changes in disease activity in newly diagnosed adult subjects with diffuse large B-cell lymphoma (DLBCL) using subcutaneous (SC) epcoritamab in combination with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP alone.","source_id_and_acronym":"CTR20231627","lead_sponsor":"AbbVie Inc. / AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. / Vetter Pharma-Fertigung GmbH \u0026 Co.KG","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"eefb2311-735a-4520-a911-fb2cba016c84","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bdb80729710b44e8a0d5eecc3ce88fb6","created_at":"2026-06-27T02:52:22.607Z","updated_at":"2026-06-27T02:52:22.607Z","phase":"Phase 3","brief_title":"A phase III, open-label, randomized controlled study comparing utedellon plus AC versus docetaxel plus AC as neoadjuvant chemotherapy for HER2-negative early high-risk or locally advanced breast cancer.","source_id_and_acronym":"CTR20223015","lead_sponsor":"Chengdu Huahao Zhongtian Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"f61b96e8-78db-47df-a0a5-dc1db8977e4e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bead4e9c4a2244bdb6633200c8818acf","created_at":"2026-06-27T03:10:51.202Z","updated_at":"2026-06-27T03:10:51.202Z","phase":"Phase 3","brief_title":"A randomized, open-label, multicenter, phase III clinical trial evaluating orelabrutinib in combination with the R-CHOP regimen versus the R-CHOP regimen in the treatment of newly diagnosed mantle cell lymphoma patients.","source_id_and_acronym":"CTR20212348","lead_sponsor":"Beijing Nuocheng Jianhua Pharmaceutical Technology Co., Ltd.","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 356","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"70651a69-ee13-49ca-bf3e-7ee3c3de6470","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=6b8a09eae47a4f57a4ca472a113ad978","created_at":"2026-06-27T03:22:41.019Z","updated_at":"2026-06-27T03:22:41.019Z","phase":"Phase 1/2","brief_title":"A study evaluating adverse events and changes in disease activity of Epcoritamab as a single subcutaneous injection or in combination with standard therapy in Chinese adult subjects with B-cell non-Hodgkin lymphoma.","source_id_and_acronym":"CTR20220304","lead_sponsor":"AbbVie Inc. / AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. / Vetter Pharma-Fertigung GmbH \u0026 Co.KG","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"a5f10edb-2ec0-49f6-a60e-eb029282468d","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=4f2ee6b8c9494607b6737c6cc7bdd9a0","created_at":"2026-06-27T03:42:20.443Z","updated_at":"2026-06-27T03:42:20.443Z","phase":"Phase 3","brief_title":"Safety and efficacy studies for treating newly diagnosed diffuse large B-cell lymphoma","source_id_and_acronym":"CTR20182377","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Delito (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 320","initiation":"Initiation: 01/10/2019","start_date":" 01/10/2019","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"b8837f12-945e-4425-8099-3e188623b01e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=7f5e58232d5a4440b550ddc20039c735","created_at":"2026-06-27T03:25:18.103Z","updated_at":"2026-06-27T03:25:18.103Z","phase":"Phase 3","brief_title":"Evaluating the efficacy and safety of orelabrutinib combined with the R-CHOP regimen versus placebo combined with the R-CHOP regimen for the treatment of newly diagnosed diffuse large B-cell lymphoma (MCD) subtype.","source_id_and_acronym":"CTR20220735","lead_sponsor":"Beijing Nuocheng Jianhua Pharmaceutical Technology Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/02/2022","start_date":" 11/02/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"d5388532-8dc0-4263-a1dd-fb1ca61b1d5e","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=2aa84007162e4b91b6659490cb60f276","created_at":"2026-06-27T03:22:50.480Z","updated_at":"2026-06-27T03:22:50.480Z","phase":"Phase 1/2","brief_title":"A study evaluating adverse events and changes in disease activity of Epcoritamab as a single subcutaneous injection or in combination with standard therapy in Chinese adult subjects with B-cell non-Hodgkin lymphoma.","source_id_and_acronym":"CTR20220331","lead_sponsor":"AbbVie Inc. / AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. / Vetter Pharma-Fertigung GmbH \u0026 Co.KG","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"10ec7324-4543-45bf-87ce-13c24b51fd1f","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=875f48cab64b4557ae78408691ad3353","created_at":"2026-06-27T04:29:59.711Z","updated_at":"2026-06-27T04:29:59.711Z","phase":"Phase 3","brief_title":"A study evaluating the efficacy of BNT323 in patients with endometrial cancer.","source_id_and_acronym":"CTR20252691","lead_sponsor":"Yingen Biopharmaceutical (Suzhou) Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • doxorubicin hydrochloride • trastuzumab pamirtecan (BNT323)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 76","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"3ae6cfc9-fe26-4cbb-9c07-05c71a11b9e0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=4abbf5139bc042acae2fc9de8d8717a4","created_at":"2026-06-27T04:03:23.902Z","updated_at":"2026-06-27T04:03:23.902Z","phase":"Phase 3","brief_title":"A multicenter phase III trial of cidamide in combination with R-CHOP for the treatment of treatment-naïve, MYC/BCL2 dual-expressing DLBCL.","source_id_and_acronym":"CTR20192684","lead_sponsor":"Shenzhen Chipscreen Pharmaceuticals Co., Ltd. / Shenzhen Chipscreen Biosciences Co., Ltd.","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • MYC rearrangement + BCL6 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC rearrangement + BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)"],"overall_status":"Completed","enrollment":" Enrollment 418","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"7782a538-610d-412c-86b6-72ac76539d71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07662928","created_at":"2026-06-27T03:55:53.178Z","updated_at":"2026-06-27T03:55:53.178Z","phase":"Phase 2","brief_title":"Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study","source_id_and_acronym":"NCT07662928","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":" | ","alterations":" LDH elevation","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 09/17/2026","start_date":" 09/17/2026","primary_txt":" Primary completion: 05/30/2031","primary_completion_date":" 05/30/2031","study_txt":" Completion: 04/30/2033","study_completion_date":" 04/30/2033","last_update_posted":"2026-06-23"},{"id":"a77b8117-3956-4cc9-966f-475061ec97af","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=2b68b2e1aa974b27846c3f267b78c7c6","created_at":"2026-06-27T04:37:34.324Z","updated_at":"2026-06-27T04:37:34.324Z","phase":"","brief_title":"Phase I/II clinical trial of TRS005 in combination with CHP for the treatment of untreated CD20-positive DLBCL patients","source_id_and_acronym":"CTR20253926","lead_sponsor":"Zhejiang Teruis Pharmaceutical Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • prednisone • TRS005"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-23"},{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"5e1e2228-b845-457c-bca6-09f91e2f7839","acronym":"","url":"https://clinicaltrials.gov/study/NCT07049848","created_at":"2025-07-05T13:58:03.171Z","updated_at":"2025-07-05T13:58:03.171Z","phase":"Phase 2","brief_title":"SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma","source_id_and_acronym":"NCT07049848","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • doxorubicin hydrochloride"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-07-03"},{"id":"be1974d5-2bf2-4a09-be82-99d0e9470dde","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965361","created_at":"2025-06-28T16:12:33.153Z","updated_at":"2025-06-28T16:12:33.153Z","phase":"","brief_title":"Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT06965361","lead_sponsor":"Ziauddin University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/02/2021","start_date":" 01/02/2021","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 07/31/2022","study_completion_date":" 07/31/2022","last_update_posted":"2025-05-16"},{"id":"4bf912ed-2f96-4d90-aef7-e45022410420","acronym":"","url":"https://clinicaltrials.gov/study/NCT00186888","created_at":"2025-07-19T13:43:51.175Z","updated_at":"2025-07-19T13:43:51.175Z","phase":"Phase 3","brief_title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","source_id_and_acronym":"NCT00186888","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" ABCG2 • CYP3A4","pipe":"","alterations":" ","tags":["ABCG2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/07/2005","start_date":" 04/07/2005","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-04-15"},{"id":"60497dbb-56e8-4c40-973c-67ee89c74186","acronym":"","url":"https://clinicaltrials.gov/study/NCT06890585","created_at":"2025-09-07T02:05:51.287Z","updated_at":"2025-09-07T02:05:51.287Z","phase":"Phase 2","brief_title":"Zanubrutinib, Chidamide, and Rituximab Induction with or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL","source_id_and_acronym":"NCT06890585","lead_sponsor":"Li Zhiming","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-24"},{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"}]